Published in
Elsevier, Annals of Oncology, (31), p. S1153-S1154, 2020
DOI: 10.1016/j.annonc.2020.08.2250
Links
Tools
LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
Journal article published in 2020 by
J. S. de Bono 
,
S. Bracarda,
C. N. Sternberg,
K. N. Chi,
D. Olmos,
S. Sandhu,
C. Massard,
N. Matsubara,
B. Alekseev,
R. Gafanov,
F. Parnis,
G. L. Buchschacher,
L. Corrales,
M. Borre,
G. Vasconcelos Alves
and other authors.
,
S. Bracarda,
C. N. Sternberg,
K. N. Chi,
D. Olmos,
S. Sandhu,
C. Massard,
N. Matsubara,
B. Alekseev,
R. Gafanov,
F. Parnis,
G. L. Buchschacher,
L. Corrales,
M. Borre,
G. Vasconcelos Alves
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 